FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897464679> ?p ?o ?g. }

• W2897464679 endingPage "70" @default.
• W2897464679 startingPage "68" @default.
• W2897464679 abstract "New technology is widening the chance of developing new pharmacological compounds and has the potential to create new jobs and have economic and societal impact on healthcare.Economic impact: The average expenditure to develop and bring to market a new drug is estimated to be approximately $2 billion, with target identification, discovery and the development of a new chemical compound before clinical trials accounting for 30% of the total cost. Commercialization of the developed platform has potential to add considerable information over the gold standard obtained by current electrophysiological tests with automated patch-clamp technology and impact the pre-screening stages of compounds, most of which is currently provided as a service by CROs and/or CMOs. Therefore, outcomes from this project have potential to carve a unique sector in the market of drug screening instrumentation. To assess this impact and available opportunities, we have secured the participation of members from academia, healthcare technology and industry to act as an advisory board for consultancy regarding knowledge transfer and commercialisation.Industrial impact: The developed system will be tested in collaboration with project partner Apconix for the development of pharmacological assays based on combinatorial chemistry approaches. Outside the immediate benefit in identifying new active compounds for the CLIC4 channel, the potential for translating the developed procedures for other pharmacologically relevant eukaryotic ion channels present cost-saving arguments against current live-cell based, large-screening assay in the Pharmaceutical industry. In addition, the collaboration with project partner Smartox will explore a further application of the technology for use with limited resources of venom samples only available in extremely small quantities that currently elude industrial automated screening. The proposed technology has the potential to greatly impact drug discovery by identifying new efficient venom-derived drugs. Together, this double partnership will enable us to address different screening needs for both SME and the Pharmaceutical Industry.Societal impact: Identification of new drug candidates from the developed technology will expand the panel of drugs with implications in cancer, mitochondrial dysfunction and neurodegenerative diseases. Improving the efficacy of identified drugs at preclinical level is expected to improve outcomes during clinical trials. Therefore, wide societal benefits would be in the form of new medicine and their improved efficacy. Furthermore, the applicability of the proposed technology to the other identified applications (see academic beneficiaries) and healthcare related fields could impact the screening of vaccines and environmental toxins, all of which will produce massive societal benefits." @default.
• W2897464679 created "2018-10-26" @default.
• W2897464679 creator A5041199955 @default.
• W2897464679 creator A5065668750 @default.
• W2897464679 date "2018-10-15" @default.
• W2897464679 modified "2023-09-27" @default.
• W2897464679 title "Droplet-based Microfluidic Platform for Intracellular Ion Channel Drug Discovery - EPSRC" @default.
• W2897464679 doi "https://doi.org/10.21820/23987073.2018.7.68" @default.
• W2897464679 hasPublicationYear "2018" @default.
• W2897464679 type Work @default.
• W2897464679 sameAs 2897464679 @default.
• W2897464679 citedByCount "1" @default.
• W2897464679 countsByYear W28974646792021 @default.
• W2897464679 crossrefType "journal-article" @default.
• W2897464679 hasAuthorship W2897464679A5041199955 @default.
• W2897464679 hasAuthorship W2897464679A5065668750 @default.
• W2897464679 hasConcept C170493617 @default.
• W2897464679 hasConcept C171250308 @default.
• W2897464679 hasConcept C185592680 @default.
• W2897464679 hasConcept C192562407 @default.
• W2897464679 hasConcept C50254741 @default.
• W2897464679 hasConcept C55493867 @default.
• W2897464679 hasConcept C74187038 @default.
• W2897464679 hasConcept C79879829 @default.
• W2897464679 hasConcept C8673954 @default.
• W2897464679 hasConceptScore W2897464679C170493617 @default.
• W2897464679 hasConceptScore W2897464679C171250308 @default.
• W2897464679 hasConceptScore W2897464679C185592680 @default.
• W2897464679 hasConceptScore W2897464679C192562407 @default.
• W2897464679 hasConceptScore W2897464679C50254741 @default.
• W2897464679 hasConceptScore W2897464679C55493867 @default.
• W2897464679 hasConceptScore W2897464679C74187038 @default.
• W2897464679 hasConceptScore W2897464679C79879829 @default.
• W2897464679 hasConceptScore W2897464679C8673954 @default.
• W2897464679 hasIssue "7" @default.
• W2897464679 hasLocation W28974646791 @default.
• W2897464679 hasOpenAccess W2897464679 @default.
• W2897464679 hasPrimaryLocation W28974646791 @default.
• W2897464679 hasRelatedWork W1998250559 @default.
• W2897464679 hasRelatedWork W2141338322 @default.
• W2897464679 hasRelatedWork W2558561277 @default.
• W2897464679 hasRelatedWork W2899084033 @default.
• W2897464679 hasRelatedWork W2912545573 @default.
• W2897464679 hasRelatedWork W2994941574 @default.
• W2897464679 hasRelatedWork W3206575557 @default.
• W2897464679 hasRelatedWork W3209917196 @default.
• W2897464679 hasRelatedWork W4210313937 @default.
• W2897464679 hasRelatedWork W4223581013 @default.
• W2897464679 hasVolume "2018" @default.
• W2897464679 isParatext "false" @default.
• W2897464679 isRetracted "false" @default.
• W2897464679 magId "2897464679" @default.
• W2897464679 workType "article" @default.